Vitadio
Company Overview
Vitadio pioneers prescription digital therapeutics aiming to reverse insulin resistance through AI-driven lifestyle modification. It offers evidence-based digital therapies focused on treating the causes of cardiometabolic diseases such as type 2 diabetes and prediabetes.
Mission and Purpose
Vitadio empowers people to restore their cardiometabolic health by creating digital therapies that treat the root causes of chronic conditions with no side effects, one habit at a time. Their digital therapeutic approach is clinically validated and comparable in effect to modern antidiabetic drugs.
Founded in 2019 and headquartered in Prague and Berlin, Vitadio provides its digital therapy services across three European countries with plans for expansion.
Key Features and Benefits
Vitadio uses AI to provide personalized therapy, real-time diet feedback, and proactive human support combining the expertise of healthcare professionals and technology.
The platform boasts high engagement rates among users, with significant clinical outcomes such as a 2.6-fold increase in patients achieving recommended HbA1c levels and 70% reporting significant weight reduction.
Collaboration and Recognition
Vitadio collaborates with major pharmaceutical companies like AstraZeneca and Novo Nordisk to augment pharmacotherapy and improve treatment adherence and outcomes.
The company has been featured in notable publications including Forbes, Die Welt, and Handelsblatt.